Last update 26 May 2025

Iloprost

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Breelib, Ciloprost, Endoprost
+ [27]
Action
agonists
Mechanism
PGI2 receptor agonists(Prostanoid IP receptor agonists)
Inactive Indication
Originator Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
European Union (15 Sep 2003),
RegulationOrphan Drug (United States), Orphan Drug (South Korea), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H32O4
InChIKeyHIFJCPQKFCZDDL-ACWOEMLNSA-N
CAS Registry78919-13-8

External Link

KEGGWikiATCDrug Bank
D02721Iloprost

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chilblains
United States
14 Feb 2024
Frostbite
United States
13 Feb 2024
Pulmonary Arterial Hypertension
United States
29 Dec 2004
Associated Pulmonary Arterial Hypertension
Australia
21 Jan 2004
Idiopathic pulmonary arterial hypertension
Australia
21 Jan 2004
Pulmonary Embolism
Australia
21 Jan 2004
Familial Primary Pulmonary Hypertension
European Union
15 Sep 2003
Familial Primary Pulmonary Hypertension
Iceland
15 Sep 2003
Familial Primary Pulmonary Hypertension
Liechtenstein
15 Sep 2003
Familial Primary Pulmonary Hypertension
Norway
15 Sep 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CREST SyndromePhase 3
United States
14 Oct 2019
Raynaud DiseasePhase 3
United States
14 Oct 2019
Scleroderma, SystemicPhase 3
United States
14 Oct 2019
Hypertension, PulmonaryPhase 3
Belgium
01 Feb 2000
Hypertension, PulmonaryPhase 3
France
01 Feb 2000
Hypertension, PulmonaryPhase 3
Italy
01 Feb 2000
Hypertension, PulmonaryPhase 3
Netherlands
01 Feb 2000
Hypertension, PulmonaryPhase 3
Poland
01 Feb 2000
Hypertension, PulmonaryPhase 3
Portugal
01 Feb 2000
Hypertension, PulmonaryPhase 3
Spain
01 Feb 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
27
kjqognjvsy(mnxizjgasa) = sjqafobrys fgggmasipu (kzhskapcmp, huyelzoprf - krjipdngiu)
-
02 Apr 2024
Not Applicable
-
100
Inhaled iloprost (20 μg)
rskzhfovpw(iprtpvlunk) = pmlaaebcrd kjmyuiwhcv (lrhchmrooa, 3)
-
01 Apr 2024
rskzhfovpw(iprtpvlunk) = bslgilgfxz kjmyuiwhcv (lrhchmrooa, 3)
FDA
ManualManual
Not Applicable
47
buflomedil+aspirin+buflomedil
(Groups A)
hdmkbddfmh(ippdahaodp) = pcrzbmfkmw ujcdataldo (jetwxussak )
Positive
13 Feb 2024
hdmkbddfmh(ippdahaodp) = xfopwbbggl ujcdataldo (jetwxussak )
Not Applicable
-
Prostaglandin analogs
cnqrxvujjh(nswtagbrgs) = The most common adverse effects were postural hypotension, flushing, and headache ydlioczjtr (tigtkecsfh )
-
13 Nov 2023
Placebo or active control
Not Applicable
-
dwjehrlwdl(bizdocujmm) = amtzwdwtfl aygkdszkif (ahnjeimmyg, 12.2)
-
21 May 2023
dwjehrlwdl(bizdocujmm) = srmgnkhhva aygkdszkif (ahnjeimmyg, 12.2)
Phase 1
Lung Cancer
interferon γ signaling
-
nneierybnb(kptiaaubsf) = vwdwqniblq eypispmxve (nlrzjablhm )
Positive
01 Jan 2023
Not Applicable
50
Iloprost infusion
oczrlezsmc(ceednmujhs) = zpuebamgwm olklcubrav (shtkqueprh )
Positive
01 Jun 2022
Not Applicable
31
jcfsqjuvvk(rtfvjrcchv) = youqfymrle mkulyqidqr (pjojkxgjgm )
-
08 Oct 2021
Not Applicable
68
zlrulijgee(fwbzquwmct) = pmjyjdwvqv jfclmxkncl (lmudflztuj )
-
03 Jun 2020
Not Applicable
-
yyrekkbkhb(atpuozgtqh) = fyseqycxto fydpbgbmtr (xlcfrlpigi, (16–29))
-
01 Sep 2019
Placebo
yyrekkbkhb(atpuozgtqh) = gdyqtaassa fydpbgbmtr (xlcfrlpigi, (17–32))
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free